[go: up one dir, main page]

BR9710808A - Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos - Google Patents

Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos

Info

Publication number
BR9710808A
BR9710808A BR9710808A BR9710808A BR9710808A BR 9710808 A BR9710808 A BR 9710808A BR 9710808 A BR9710808 A BR 9710808A BR 9710808 A BR9710808 A BR 9710808A BR 9710808 A BR9710808 A BR 9710808A
Authority
BR
Brazil
Prior art keywords
pyrimido
pyrite
containing substituted
bicyclic derivatives
bicyclic
Prior art date
Application number
BR9710808A
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9710808A publication Critical patent/BR9710808A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR9710808A 1996-08-06 1997-07-23 Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos BR9710808A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2345396P 1996-08-06 1996-08-06
PCT/IB1997/000918 WO1998005661A1 (en) 1996-08-06 1997-07-23 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Publications (1)

Publication Number Publication Date
BR9710808A true BR9710808A (pt) 1999-08-17

Family

ID=21815208

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710808A BR9710808A (pt) 1996-08-06 1997-07-23 Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos

Country Status (40)

Country Link
US (1) US6492520B1 (pt)
EP (1) EP0920429B1 (pt)
JP (1) JP3345021B2 (pt)
KR (1) KR20000029843A (pt)
CN (1) CN1093130C (pt)
AP (1) AP1096A (pt)
AR (1) AR008829A1 (pt)
AT (1) ATE232863T1 (pt)
AU (1) AU709203B2 (pt)
BG (1) BG103143A (pt)
BR (1) BR9710808A (pt)
CA (1) CA2262692C (pt)
CO (1) CO4900060A1 (pt)
CZ (1) CZ292806B6 (pt)
DE (1) DE69719193T2 (pt)
DK (1) DK0920429T3 (pt)
DZ (1) DZ2289A1 (pt)
EA (1) EA003188B1 (pt)
ES (1) ES2191183T3 (pt)
GT (1) GT199700089A (pt)
HR (1) HRP970432B1 (pt)
ID (1) ID17980A (pt)
IL (1) IL128188A0 (pt)
IS (1) IS4948A (pt)
MA (1) MA24296A1 (pt)
NO (1) NO313293B1 (pt)
NZ (1) NZ333727A (pt)
OA (1) OA10970A (pt)
PA (1) PA8435201A1 (pt)
PE (1) PE97098A1 (pt)
PL (1) PL331602A1 (pt)
SA (1) SA97180334A (pt)
SK (1) SK14099A3 (pt)
TN (1) TNSN97135A1 (pt)
TR (1) TR199900228T2 (pt)
TW (1) TW550265B (pt)
UY (1) UY24655A1 (pt)
WO (1) WO1998005661A1 (pt)
YU (1) YU5399A (pt)
ZA (1) ZA976954B (pt)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6599910B1 (en) 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
CA2349904A1 (en) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
JP2002529465A (ja) 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびｃｒｆレセプターアンタゴニストに関する方法
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress
WO2001062718A1 (en) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Benzamide derivative and use thereof
MY141144A (en) * 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0011964D0 (en) 2000-05-18 2000-07-05 Suyal N Thick glass films with controlled refractive indices and their applications
WO2002059083A2 (en) * 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
HRP20040309A2 (en) 2001-09-26 2006-05-31 Bayer Pharmaceuticals Corporation 1,6-nafthyridine derivatives as antidiabetics
JP4603268B2 (ja) 2002-04-19 2010-12-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ES2338545T3 (es) 2002-12-20 2010-05-10 Pfizer Products Inc. Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
WO2005020910A2 (en) * 2003-08-27 2005-03-10 Pharmacia Corporation Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries
EP1732541A4 (en) * 2004-04-07 2008-03-05 Takeda Pharmaceutical CYCLIC COMPOUNDS
MXPA06013165A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
SG160438A1 (en) * 2005-03-25 2010-04-29 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5- d]pyrimidin-2(1h)-one derivatives
UY29439A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
US20090137550A1 (en) * 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
EP2325171B1 (en) 2005-05-26 2013-10-09 Aldexa Therapeutics, Inc. Quinoline derivatives for treating retinal diseases
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
US7763731B2 (en) 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
RU2441010C2 (ru) * 2005-12-21 2012-01-27 Эбботт Лэборетриз Противовирусные соединения
CA2633757A1 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
US8551996B2 (en) * 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
ES2661850T3 (es) 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
US9814701B2 (en) 2009-12-11 2017-11-14 Aldeyra Therapeutics, Inc. Compositions and methods for the treatment of macular degeneration
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CN105120866B (zh) 2013-01-23 2020-02-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｆｇｆｒ抑制剤としての二環式複素環
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
CR20160518A (es) * 2014-05-15 2017-02-21 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
ES2845205T3 (es) 2014-09-16 2021-07-26 Gilead Sciences Inc Métodos para preparar moduladores de receptores tipo Toll
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
WO2017003724A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
DK3413892T3 (da) 2016-02-12 2022-05-23 Cytokinetics Inc Tetrahydroisoquinolinderivater
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
US11040039B2 (en) * 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
CN119241541A (zh) 2018-05-04 2025-01-03 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
PE20210919A1 (es) 2018-05-04 2021-05-19 Incyte Corp Sales de un inhibidor de fgfr
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
US11197821B2 (en) 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
IL293001A (en) 2019-12-04 2022-07-01 Incyte Corp Derivatives of fgfr repressors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
DK0674641T3 (da) * 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
EP0765327B1 (en) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
JP2898887B2 (ja) * 1994-08-31 1999-06-02 沖電気工業株式会社 Ｉｃカードの読み取り装置
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
DE69603240T2 (de) * 1995-05-12 2000-01-05 Neurogen Corp., Branford Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
DK0778277T3 (da) * 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
ES2168237T3 (es) 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same

Also Published As

Publication number Publication date
KR20000029843A (ko) 2000-05-25
CN1227552A (zh) 1999-09-01
AR008829A1 (es) 2000-02-23
HK1021734A1 (en) 2000-06-30
US6492520B1 (en) 2002-12-10
ES2191183T3 (es) 2003-09-01
WO1998005661A1 (en) 1998-02-12
AP9701052A0 (en) 1997-10-31
MA24296A1 (fr) 1998-04-01
PE97098A1 (es) 1999-01-12
EA003188B1 (ru) 2003-02-27
DE69719193D1 (de) 2003-03-27
ID17980A (id) 1998-02-12
NO990544L (no) 1999-03-31
TR199900228T2 (xx) 1999-03-22
EP0920429A1 (en) 1999-06-09
NZ333727A (en) 2000-09-29
UY24655A1 (es) 2000-09-29
IL128188A0 (en) 1999-11-30
GT199700089A (es) 1999-01-26
IS4948A (is) 1999-01-19
JP2000501116A (ja) 2000-02-02
CA2262692C (en) 2002-06-11
YU5399A (sh) 2002-03-18
TW550265B (en) 2003-09-01
AP1096A (en) 2002-08-26
PA8435201A1 (es) 1999-12-27
CZ41199A3 (cs) 2000-01-12
HRP970432A2 (en) 1998-08-31
CO4900060A1 (es) 2000-03-27
EP0920429B1 (en) 2003-02-19
DE69719193T2 (de) 2003-09-25
ZA976954B (en) 1999-02-05
SK14099A3 (en) 2000-05-16
CN1093130C (zh) 2002-10-23
AU709203B2 (en) 1999-08-26
ATE232863T1 (de) 2003-03-15
JP3345021B2 (ja) 2002-11-18
CA2262692A1 (en) 1998-02-12
EA199900083A1 (ru) 1999-08-26
SA97180334A (ar) 2005-12-03
OA10970A (en) 2001-11-05
BG103143A (en) 1999-09-30
TNSN97135A1 (fr) 2005-03-15
NO313293B1 (no) 2002-09-09
DZ2289A1 (fr) 2002-12-25
CZ292806B6 (cs) 2003-12-17
DK0920429T3 (da) 2003-05-12
HRP970432B1 (en) 2002-10-31
AU3356397A (en) 1998-02-25
PL331602A1 (en) 1999-08-02
NO990544D0 (no) 1999-02-05

Similar Documents

Publication Publication Date Title
BR9710808A (pt) Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
PT946542E (pt) Derivados de indano ou de di-hidroindol
ATE216999T1 (de) Pyrimidin-4-on derivate als pestizidesmittel
FI960399A7 (fi) Perhydroisoindolijohdannaisia P-aineen antagonisteina
DK0845520T3 (da) Stabiliserede væsker, der indeholder opløselig zink
BR9711970A (pt) Derivados 6,5-substitu¡do-heterobic¡clicos
FI944729L (fi) Perhydroisoindolijohdannaiset substanssi P:n antagonisteina
BR9500638A (pt) Composição de poliacetal
ATE264327T1 (de) Substituierte 6,6-heterobicyclische derivate
PT901474E (pt) Derivados de aril-pirimidina.
PT934320E (pt) Derivados de naftiridina
BR9701294A (pt) Composição geradora de gás
PT891332E (pt) Derivados de 6-fenilpiridil-2-amina
DE69723714D1 (de) Koaleszenzelement
BR9700850A (pt) Derivados de quinazolina substituídos
FI945538L (fi) 7-(2-Aminoetyyli)-bentsotiatsolonit
BR9709065A (pt) Derivados de alquilaminobenzotiazole e-benzoxazol
DK0842991T3 (da) Grundersammensætning
BR9407550A (pt) Composiçao contendo derivados de fosfato
DE69002024D1 (de) Bioaktive laktoferrin derivate.
PT906279E (pt) Derivados de pirrol
NL1005675A1 (nl) Polytriazinederivaten-bevattende polyalkylpiperidinyloxy- of polyalkylpiperidinylaminogroepen.
DE69712090D1 (de) Frankiermaschinen
NO985084D0 (no) Vial
DE69719372D1 (de) BAUTEILBEHäLTER

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERACAO DA INT.CL.8: C07D 217/22, A61K 31/00, A61K 31/435, A61K 31/4353, A61K 31/436, A61K 31/437, A61K 31/4375, A61K 31/5365, A61K 31/4985, A61K 31/505, A61K 31/519, A61K 31/535, A61K 31/5365, A61P 3/04, A61P 5/38, A61P 25/28, A61P 43/00, C07D 217/24, C07D 471/04, C07D 419/502, C07D 498/04

Ipc: C07D 217/22 (2007.01), A61K 31/00 (2007.01), A61K

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements